AU2003238370B2 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same - Google Patents

Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same Download PDF

Info

Publication number
AU2003238370B2
AU2003238370B2 AU2003238370A AU2003238370A AU2003238370B2 AU 2003238370 B2 AU2003238370 B2 AU 2003238370B2 AU 2003238370 A AU2003238370 A AU 2003238370A AU 2003238370 A AU2003238370 A AU 2003238370A AU 2003238370 B2 AU2003238370 B2 AU 2003238370B2
Authority
AU
Australia
Prior art keywords
framework
single chain
antibody
sequence
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003238370A
Other languages
English (en)
Other versions
AU2003238370A1 (en
Inventor
Adrian Auf Der Maur
Alcide Barberis
Dominik Escher
Stefan Ewert
Kathrin Tissot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003238370A1 publication Critical patent/AU2003238370A1/en
Assigned to ESBATech AG, an Alcon Biomedical Research Unit LLC reassignment ESBATech AG, an Alcon Biomedical Research Unit LLC Amend patent request/document other than specification (104) Assignors: ESBATECH AG
Application granted granted Critical
Publication of AU2003238370B2 publication Critical patent/AU2003238370B2/en
Assigned to ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC reassignment ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC Amend patent request/document other than specification (104) Assignors: ESBATech AG, an Alcon Biomedical Research Unit LLC
Priority to AU2010202634A priority Critical patent/AU2010202634B2/en
Priority to AU2012211497A priority patent/AU2012211497C1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003238370A 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same Expired AU2003238370B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2010202634A AU2010202634B2 (en) 2002-05-22 2010-06-24 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2012211497A AU2012211497C1 (en) 2002-05-22 2012-08-01 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US60/382,649 2002-05-22
US43825603P 2003-01-03 2003-01-03
US60/438,256 2003-01-03
PCT/EP2003/005324 WO2003097697A2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202634A Division AU2010202634B2 (en) 2002-05-22 2010-06-24 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Publications (2)

Publication Number Publication Date
AU2003238370A1 AU2003238370A1 (en) 2003-12-02
AU2003238370B2 true AU2003238370B2 (en) 2010-04-29

Family

ID=29553590

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003238370A Expired AU2003238370B2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2010202634A Expired AU2010202634B2 (en) 2002-05-22 2010-06-24 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202634A Expired AU2010202634B2 (en) 2002-05-22 2010-06-24 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Country Status (14)

Country Link
US (5) US8853362B2 (enExample)
EP (5) EP2314622B1 (enExample)
JP (10) JP2006508638A (enExample)
CN (4) CN1662556B (enExample)
AU (2) AU2003238370B2 (enExample)
CA (2) CA2483285C (enExample)
CY (1) CY1114225T1 (enExample)
DK (2) DK1506236T3 (enExample)
ES (3) ES2399617T3 (enExample)
HU (1) HUE048922T2 (enExample)
NZ (1) NZ536412A (enExample)
PT (2) PT2332989E (enExample)
SI (2) SI2332989T1 (enExample)
WO (1) WO2003097697A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
JP5171611B2 (ja) 2005-03-25 2013-03-27 ナショナル リサーチ カウンシル オブ カナダ 可溶性ポリペプチドの単離方法
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
KR101457223B1 (ko) 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
ES2820837T3 (es) * 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
RU2009137582A (ru) * 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (en) * 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
KR102050040B1 (ko) * 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
KR20210097819A (ko) * 2008-06-25 2021-08-09 노바르티스 아게 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AU2009270405B2 (en) 2008-06-30 2014-06-05 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
EP2769711A1 (en) 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
MX352922B (es) * 2009-02-24 2017-12-14 Esbatech Alcon Biomed Res Unit Métodos para identificar inmunoligadores de los antígenos de la superficie celular.
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CA2845391C (en) 2011-08-18 2021-01-19 Affinity Biosciences Pty Ltd Soluble polypeptides
CA2850572A1 (en) 2011-10-20 2013-04-25 Esbatech, A Novartis Company Llc Stable multiple antigen-binding antibody
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
BR112015009892B1 (pt) 2012-11-05 2022-12-27 Delenex Therapeutics Ag Anticorpo contra il-1 beta, seu método de produção e seu uso, sequência isolada de ácido nucleico, vetor, composição cosmética, de diagnóstico ou farmacêutica, e kit
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
JP2016506974A (ja) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
CA2896174A1 (en) * 2013-02-20 2014-08-28 Esbatech - A Novartis Company Llc Acceptor framework for cdr grafting
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MY196631A (en) 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
CN109952112B (zh) 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2019199941A1 (en) * 2018-04-10 2019-10-17 Northwestern University Extracellular vesicles comprising targeting affinity domain-based membrane proteins
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
JP2024509973A (ja) 2021-03-10 2024-03-05 マビュロン アーゲー Ｔｄｐ－４３に対する抗体およびその使用方法
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) * 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
WO1999028502A1 (en) 1997-11-28 1999-06-10 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
ATE273323T1 (de) * 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cheadle et al, Molecular Immunology., 1992, Vol. 29, No. 1, pp. 21-30 *
Visintin M. et al, Journal of Molecular Biology, 2002, Vol. 317, No. 1, pp. 73-83 *

Also Published As

Publication number Publication date
NZ536412A (en) 2008-10-31
JP2006508638A (ja) 2006-03-16
CN1662556B (zh) 2013-05-01
JP2013078343A (ja) 2013-05-02
US20150057191A1 (en) 2015-02-26
HK1217712A1 (en) 2017-01-20
DK1506236T3 (da) 2013-03-04
HUE048922T2 (hu) 2020-09-28
JP2019058191A (ja) 2019-04-18
AU2010202634B2 (en) 2012-08-23
ES2399617T3 (es) 2013-04-02
EP3656787A1 (en) 2020-05-27
JP2020171286A (ja) 2020-10-22
EP2314622B1 (en) 2017-10-18
AU2010202634A1 (en) 2010-07-15
US20200165322A1 (en) 2020-05-28
PT2332989E (pt) 2015-08-05
CN105175535A (zh) 2015-12-23
EP2947095A1 (en) 2015-11-25
AU2003238370A1 (en) 2003-12-02
HK1071378A1 (en) 2005-07-15
CA2867542A1 (en) 2003-11-27
HK1152320A1 (en) 2012-02-24
ES2537104T3 (es) 2015-06-02
DK2332989T3 (en) 2015-05-11
EP2314622A1 (en) 2011-04-27
CA2483285A1 (en) 2003-11-27
CA2483285C (en) 2015-01-27
CN102093477B (zh) 2014-02-26
EP2947095B1 (en) 2019-10-02
JP6261136B2 (ja) 2018-01-17
CY1114225T1 (el) 2016-08-31
CN102093477A (zh) 2011-06-15
JP2015214583A (ja) 2015-12-03
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
PT1506236E (pt) 2013-03-27
JP6075836B2 (ja) 2017-02-08
EP2332989A1 (en) 2011-06-15
JP6100544B2 (ja) 2017-03-22
US20190119361A1 (en) 2019-04-25
CN103739706B (zh) 2015-11-18
JP2010187678A (ja) 2010-09-02
EP1506236B1 (en) 2013-01-23
SI2332989T1 (sl) 2015-06-30
JP2012228272A (ja) 2012-11-22
CA2867542C (en) 2020-04-14
JP2017201990A (ja) 2017-11-16
CN1662556A (zh) 2005-08-31
US8853362B2 (en) 2014-10-07
JP2013256533A (ja) 2013-12-26
WO2003097697A2 (en) 2003-11-27
EP1506236A2 (en) 2005-02-16
EP2332989B1 (en) 2015-04-01
JP6918033B2 (ja) 2021-08-11
JP2015227372A (ja) 2015-12-17
US20170107272A1 (en) 2017-04-20
US20060035320A1 (en) 2006-02-16
CN103739706A (zh) 2014-04-23
WO2003097697A3 (en) 2004-12-09
US10125186B2 (en) 2018-11-13
US10570190B2 (en) 2020-02-25
ES2656427T3 (es) 2018-02-27

Similar Documents

Publication Publication Date Title
AU2003238370B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2013203288B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2012211497B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2015202410A1 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1217712B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1071378B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804A (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1152320B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 4, PAGE(S) 882 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME ESBATECH AG, APPLICATION NO. 2003238370, UNDER INID (71) CORRECT THE APPLICANT NAME TO ESBATECH AG.

Free format text: IN VOL 17, NO 36, PAGE(S) 12972 UNDER THE HEADING COMPLETE APPLICATIONS FILED -NAME INDEX UNDER THE NAME ESBATECH AG, APPLICATION NO. 2003238370, UNDER INID (71) CORRECT THE APPLICANT NAME TO ES- BATECH AG.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired